CDC801

CAS No. 192819-27-5

CDC801( CDC-801 )

Catalog No. M26097 CAS No. 192819-27-5

CDC801 is a potent and orally active inhibitor of PDE4 and TNF-α (IC50: 1.1 μM and 2.5 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 358 Get Quote
5MG 560 Get Quote
10MG 799 Get Quote
25MG 1197 Get Quote
50MG 1611 Get Quote
100MG 2187 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CDC801
  • Note
    Research use only, not for human use.
  • Brief Description
    CDC801 is a potent and orally active inhibitor of PDE4 and TNF-α (IC50: 1.1 μM and 2.5 μM).
  • Description
    CDC801 is a potent and orally active inhibitor of PDE4 and TNF-α (IC50: 1.1 μM and 2.5 μM).
  • In Vitro
    The more detailed information refer to the Compound 6b in the reference 1 (PMID:19256507).
  • In Vivo
    ——
  • Synonyms
    CDC-801
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    Potassium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    192819-27-5
  • Formula Weight
    408.454
  • Molecular Formula
    C23H24N2O5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 16.67 mg/mL (40.81 mM)
  • SMILES
    COc1ccc(cc1OC1CCCC1)C(CC(N)=O)N1C(=O)c2ccccc2C1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hamilton KL,et al. DCEBIO stimulates Cl- secretion in the mouse jejunum. Am J Physiol Cell Physiol. 2006 Jan;290(1):C152-64.
molnova catalog
related products
  • CDC801

    CDC801 is a potent and orally active inhibitor of PDE4 and TNF-α (IC50: 1.1 μM and 2.5 μM).

  • Cucurbitacin IIA

    Cucurbitacin IIA can induce apoptosis and enhance autophagy, contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases.

  • Conatumumab

    Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5.